The Biotechnology Industry Organization (BIO) will hold its Intellectual Property Counsels Committee Spring Conference and Meeting in Seattle, Washington from April 13-15.
When you see “Get Your Flu Vaccine Here” signs and banners outside pharmacies and in doctor’s offices, you might think, “isn’t it too late for that?” The answer is no.
Personalized medicine has the potential to revolutionize patient care. The fundamental goal in advancing our healthcare system through personalized medicine is to deliver the right treatment to the right patient at the right time.
A report by Health Advances found that significant limitations in the current reimbursement system for novel diagnostics lead to inconsistent coverage decisions and impede the investment necessary for the development of the next generation of diagnostics.
Sara Radcliffe, BIO Executive Vice President Health, presents an overview of BIO's commissioned study on Diagnostics Reimbursement at the Harvard Medical Center Partners Healthcare Personalized Medicine Conference: Impacting Healthcare.
A biologic is manufactured in a living system such as a microorganism, or plant or animal cells. Most biologics are very large, complex molecules or mixtures of molecules. Many biologics are produced using recombinant DNA technology.
In this presentation, BIO urges the Food and Drug Administration to prioritize patient safety and incentives for innovation at a public hearing on biosimilars.